UCB-SP506

Study Sponsor : UCB

Study Title

A multicenter, randomized, double-blind, placebo-controlled, parallel-group,
dose-ranging study to assess the efficacy, safety, and tolerability of escalating transdermal
doses of rotigotine (SPM 962) in subjects with early-stage Parkinson’s disease

Medicine or Vaccine (generic name)

Rotigotine

Sponsor Identification Number

SP506

Trial Registry Identification Number(#'s)

Not available

Medical Condition

Parkinson's Disease

Phase

Phase 2

Link to study details on the UCB Clinical Study Register

Not available

Link to study details on ClinicalTrials.gov (if available)

Not available

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Currently not available on Sponsor Clinical Study Registry but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements

Date Added to this Site

July 2014